IDEAYA and Genentech Advance KRAS G12D Cancer Trial
South San Francisco, California, August 19, 2026 IDEAYA Biosciences has entered into a clinical collaboration with Genentech, a member...
Precision Oncology
Advertisement
Amygdala Advances ANS-858 After FDA IND Clearance
PALO ALTO, Calif., August 18, 2026 Amygdala Neurosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Lantheus Wins FDA Approval for Tau PET Agent in Alzheimer’s
Bedford, Massachusetts, August 14, 2026 Lantheus Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved...
BioSapien Nominated for 2026 Prix Galien Best Startup Award
San Diego, California, August 14, 2026 BioSapien Inc., a biotechnology company developing localized drug-delivery technologies for cancer treatment, has...
Cerenome Secures HCSC Agreement, Expanding CNSide Coverage
Houston, USA — August 13, 2026 Cerenome, Inc. announced that its wholly owned subsidiary CNSide Diagnostics, LLC has signed...
Advertisements
LeonaBio Advances Lasofoxifene Phase 3 Breast Cancer Trial
BOTHELL, Wash., Aug. 14, 2026 LeonaBio, Inc. reported continued progress in the Phase 3 ELAINE-3 clinical trial evaluating lasofoxifene...
PMV Pharmaceuticals Completes PYNNACLE Ovarian Cancer Enrollment
PRINCETON, N.J., Aug. 14, 2026 PMV Pharmaceuticals, Inc. reported continued progress in its Phase 2 PYNNACLE clinical trial evaluating...
Lantern Pharma Advances AI-Driven Drug Discovery Strategy
DALLAS, Aug. 14, 2026 Lantern Pharma Inc. is strengthening its position at the intersection of artificial intelligence and precision...
Freenome Gains FDA Breakthrough Device Designation
Brisbane, California, August 12, 2026 Freenome, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...
Taiho Oncology Advances Zipalertinib in Phase 3 Trial
Princeton, New Jersey, Tokyo, Japan & Cambridge, Massachusetts, August 12, 2026 Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced...
Advertisement
